High-Throughput Screening Platform for Cancer Drug Discovery

Information

  • Research Project
  • 10163816
  • ApplicationId
    10163816
  • Core Project Number
    R33CA240191
  • Full Project Number
    5R33CA240191-02
  • Serial Number
    240191
  • FOA Number
    RFA-CA-19-020
  • Sub Project Id
  • Project Start Date
    6/1/2020 - 4 years ago
  • Project End Date
    5/31/2023 - a year ago
  • Program Officer Name
    MCKEE, TAWNYA C
  • Budget Start Date
    6/1/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    6/16/2021 - 3 years ago

High-Throughput Screening Platform for Cancer Drug Discovery

Project Summary Targeted therapies have shown great promise in the treatment of cancer. High-throughput screening (HTS) campaigns have often relied on assays using labeled ligands or enzyme substrates. Artifacts associated with labeling have led to the erroneous identification of compounds that act in on the labeled substrate rather than the intended target. A label-free, solution-based HTS method will facilitate identification of compounds acting specifically on the intended targets. The goals of this proposed project are to advance development and validate this calorimetry platform as an accessible approach for high throughput ITC analysis, demonstrating its advantages to study a variety of cancer therapeutic targets. To achieve this goal, we will improve mixing of reagents in droplets, multiplex temperature readout from individual droplets, automate fluidic handling and data analysis, and validate the applicability of the improved technology to study: 1) SH2 domain/phosphopeptide interactions, 2) spleen tyrosine kinase (Syk) enzyme activity, and 3) Bromodomain/acetylated histone peptide interactions, further applied in small molecule screening. The realization of the spectro-optical calorimetry technology platform will enable full thermodynamic characterization of binding and enzymatic reactions at the throughput of 1536-well plate assays but with significantly reduced assay development time and larger numbers of repeats and analyte concentrations. The combination of increased throughput and reduced sample consumption will change the way researchers view calorimetry: rather than being seen as a technique for a limited number of high-value measurements, it will be viewed as a primary screening method for cancer therapeutic targets.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R33
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    294576
  • Indirect Cost Amount
    374441
  • Total Cost
    669017
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:669017\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PALO ALTO RESEARCH CENTER
  • Organization Department
  • Organization DUNS
    112219014
  • Organization City
    PALO ALTO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    943041314
  • Organization District
    UNITED STATES